PCC0105005

PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC50 = 77.91 nM) . PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine[1].

Product Specifications

CAS Number

2921670-99-5

UNSPSC

12352005

Target

5-HT Receptor; CGRP Receptor; Epigenetic Reader Domain; ERK

Related Pathways

Epigenetics; GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; Stem Cell/Wnt

Field of Research

Neurological Disease

Smiles

CN(CC1)CCC1C2=CNC3=CC=C(NC(C4=CC(C=C(C5CCN(C(N[C@H](CC6=CC(C)=C(NN=C7)C7=C6)C(N8CCN(C9CCN(C)CC9)CC8)=O)=O)CC5)C(N%10)=O)=C%10C=C4)=O)C=C32

Molecular Formula

C51H63N11O4

Molecular Weight

894.12

References & Citations

[1]Zou F, et al. Structure-guided rational design of dual-target CGRP antagonist/5HT1F agonist therapeutics for migraine. Eur J Med Chem. 2026 Jan 15;302 (Pt 3) :118361.